https://validator.w3.org/feed/docs/rss2.html Contact Science About Christopher Tan Cheng-I Wang Albatroz Therapeutics Soars in “Leading Biotech Companies in Singapore 2025” List Albatroz Therapeutics Secure $3 Million to Develop First-ever Therapy Blocking a Universal Process Involved in the Growth and Spread of Cancerous Solid Tumors and Arthritic Cartilage Degradation Nature Communications Publishes Pivotal Data From Albatroz Therapeutics Demonstrating That Inhibiting Calnexin Alleviates Arthritis Symptoms and May Reverse Disease Progression Frederic Bard ALB-03 ALB-04 ALB-02 Albatroz Therapeutics Soars into Johnson & Johnson Innovation – JLABS Singapore Roberto Iacone, MD David Virshup, MD ER O-glycosylation in synovial fibroblasts drives cartilage degradation. Andreas Wallnoefer, Ph.D., MBA BioWorld Recognizes Albatroz Science, Leadership, and Progress Toward Blocking a Highly Specific Target to Block Growth and Spread of Solid Tumors and Cartilage Degradation Albatroz Co-Founder Presents at the ‘Biomedical Innovation in Asia’ Workshop Albatroz Co-Founder and CEO, Dr. Fredric Bard is spotlighted by A*STAR – Agency for Science, Technology and Research for his insights as a scientist-entrepreneur Albatroz Featured in the Novo Nordisk Singapore Partnering Day 2023 ALB-01 Regulation of O-glycosylation through Golgi-to-ER relocation of initiation enzymes. ERK8 is a negative regulator of O-GalNAc glycosylation and cell migration. Short O-GalNAc glycans: regulation and role in tumor development and clinical perspectives. Cracking the glycome encoder: signaling, trafficking, and glycosylation. Organelle Specific O-Glycosylation Drives MMP14 Activation, Tumor Growth, and Metastasis. The GalNAc-T Activation (GALA) Pathway: Drivers and markers. Src activates retrograde membrane traffic through phosphorylation of GBF1. Amgen and NSG Biolabs Announce Albatroz Therapeutics as Winner of First Amgen Golden Ticket in Singapore Albatroz Therapeutics Selected as Finalist in the 2020 Brace Award Venture Competition Albatroz Named One of Six Companies Leading Singapore’s Biotech Scene Albatroz Therapeutics Featured in A *STAR Research Highlights In Vivo Spotlights Albatroz’s Science and the Leadership of Guy Heathers Initiation of GalNAc-type O-glycosylation in the endoplasmic reticulum promotes cancer cell invasiveness. ER-resident oxidoreductases are glycosylated and trafficked to the cell surface to promote matrix degradation by tumour cells. Guy Heathers Kristina Rutkute Florian Schuster Albatroz Therapeutics